Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 9, Pages 1320
Publisher
MDPI AG
Online
2019-09-09
DOI
10.3390/cancers11091320
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis
- (2019) Amirali B. Bukhari et al. JOURNAL OF CLINICAL INVESTIGATION
- Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine
- (2019) Zay Yar Oo et al. Molecular Oncology
- Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
- (2018) A Italiano et al. ANNALS OF ONCOLOGY
- The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells
- (2018) Laurence Booth et al. CANCER BIOLOGY & THERAPY
- Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine
- (2018) Siang-Boon Koh et al. CANCER RESEARCH
- The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer
- (2018) Alice Lallo et al. CLINICAL CANCER RESEARCH
- Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 InhibitorsIn Vivo
- (2018) Zay Yar Oo et al. CLINICAL CANCER RESEARCH
- Targeting the replication stress response in cancer
- (2018) Josep V. Forment et al. PHARMACOLOGY & THERAPEUTICS
- Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance
- (2018) Jone Michelena et al. Nature Communications
- ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation
- (2018) Frank P. Vendetti et al. JOURNAL OF CLINICAL INVESTIGATION
- Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models
- (2018) Caitlin D Lowery et al. CLINICAL CANCER RESEARCH
- Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe
- (2018) Nicholas Warren et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors
- (2017) Leslie A. Parsels et al. MOLECULAR CANCER RESEARCH
- The impact of replication stress on replication dynamics and DNA damage in vertebrate cells
- (2017) Hervé Técher et al. NATURE REVIEWS GENETICS
- The essential kinase ATR: ensuring faithful duplication of a challenging genome
- (2017) Joshua C. Saldivar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma
- (2017) V Colicchia et al. ONCOGENE
- Shortage of dNTPs underlies altered replication dynamics and DNA breakage in the absence of the APC/C cofactor Cdh1
- (2017) J Garzón et al. ONCOGENE
- Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases
- (2017) Jonathan P. McNally et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor
- (2017) Ryan Montano et al. Oncotarget
- Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy
- (2016) Andrew J. Massey CANCER LETTERS
- Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
- (2016) Jeffrey R. Infante et al. CLINICAL CANCER RESEARCH
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells
- (2016) Samantha S.W. Ho et al. IMMUNITY
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
- (2016) Kumar Sanjiv et al. Cell Reports
- Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
- (2015) Christopher J. Lord et al. Annual Review of Medicine
- Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
- (2015) Sophia X. Pfister et al. CANCER CELL
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- ATR-Mediated Phosphorylation of FANCI Regulates Dormant Origin Firing in Response to Replication Stress
- (2015) Yu-Hung Chen et al. MOLECULAR CELL
- Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase
- (2015) Rémi Buisson et al. MOLECULAR CELL
- Cancer risk: Role of environment--Response
- (2015) C. Tomasetti et al. SCIENCE
- The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
- (2015) Mike I. Walton et al. Oncotarget
- A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase
- (2015) Nandini Sakurikar et al. Oncotarget
- Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
- (2014) Lucas de Sousa Cavalcante et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo
- (2013) Ryan Montano et al. BMC CANCER
- ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA
- (2013) Luis Ignacio Toledo et al. CELL
- Identification of Preferred Chemotherapeutics for Combining with aCHK1Inhibitor
- (2013) Yang Xiao et al. MOLECULAR CANCER THERAPEUTICS
- Causes and consequences of replication stress
- (2013) Michelle K. Zeman et al. NATURE CELL BIOLOGY
- Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
- (2012) M. R. Russell et al. CANCER RESEARCH
- Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair
- (2012) Vincenzo D'Angiolella et al. CELL
- Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo
- (2012) Laura Carrassa et al. CELL CYCLE
- A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress
- (2012) K Brooks et al. ONCOGENE
- The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition
- (2012) Ruth Thompson et al. PLoS One
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- Hydroxyurea: a key player in cancer chemotherapy
- (2011) Kapish Madaan et al. Expert Review of Anticancer Therapy
- Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites
- (2011) R. Montano et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
- (2011) P T Ferrao et al. ONCOGENE
- Structure-Specific DNA Endonuclease Mus81/Eme1 Generates DNA Damage Caused by Chk1 Inactivation
- (2011) Josep V. Forment et al. PLoS One
- Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase
- (2010) Halfdan Beck et al. JOURNAL OF CELL BIOLOGY
- Chk1 inhibits replication factory activation but allows dormant origin firing in existing factories
- (2010) Xin Quan Ge et al. JOURNAL OF CELL BIOLOGY
- Increased origin activity in transformed versus normal cells: identification of novel protein players involved in DNA replication and cellular transformation
- (2010) Domenic Di Paola et al. NUCLEIC ACIDS RESEARCH
- Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
- (2010) Cynthia X. Ma et al. TRENDS IN MOLECULAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now